Evidence map›Paper›PMID 35636166›Full record

ArticlePhytomedicine : international journal of phytotherapy and phytopharmacology2022

Glycyrrhetinic acid: A potential drug for the treatment of COVID-19 cytokine storm.

Huawei Li, Jia You, Xi Yang, Yuanfeng Wei, Lingnan Zheng, Yaqin Zhao, Ying Huang, Zhao Jin, Cheng Yi

Open access · greenAbstract read
In one paragraph

Article in Phytomedicine : international journal of phytotherapy and phytopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Potential candidates from a functional foodFrontiers in endocrinology · 2024
    Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. BioMedicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Huawei LiDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, No.37 Guoxue Lane, Chengdu 610041, China; Department of Oncology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China.
Jia YouDepartment of Oncology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China.
Xi YangDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, No.37 Guoxue Lane, Chengdu 610041, China.
Yuanfeng WeiDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, No.37 Guoxue Lane, Chengdu 610041, China.
Lingnan ZhengDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, No.37 Guoxue Lane, Chengdu 610041, China.
Yaqin ZhaoDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, No.37 Guoxue Lane, Chengdu 610041, China.
Ying HuangWest China School of Basic Medical Science and Forensic Medicine, Sichuan University, Chengdu 610044, China.
Zhao JinSchool of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China. Electronic address: dr.jinzhao@qq.com.
Cheng YiDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, No.37 Guoxue Lane, Chengdu 610041, China. Electronic address: yicheng6834@126.com.
Sichuan University · CNChengdu University of Traditional Chinese Medicine · CNWest China Medical Center of Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe cytokine storm (CS) triggered by coronavirus disease 2019 (COVID-19) has caused serious harm to health of humanity and huge economic burden to the world, and there is a lack of effective methods to treat this complication. PURPOSE: In this research, we used network pharmacology and molecular docking to reveal the interaction mechanism in the glycyrrhetinic acid (GA) for the treatment of CS, and validated the effect of GA intervention CS by experiments. STUDY

designFirst, we screened corresponding target of GA and CS from online databases, and obtained the action target genes through the Venn diagram. Then, protein-protein interaction (PPI) network, Gene ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment of the action target genes were acquired by R language to predict its mechanism. Next, molecular docking was performed on core targets. Finally, experiments in which GA intervened in lipopolysaccharide (LPS)-induced CS were implemented.

results84 action target genes were obtained from online database. The PPI network of target genes showed that TNF, IL6, MAPK3, PTGS2, ESR1 and PPARG were considered as the core genes. The results of GO and KEGG showed that action target genes were closely related to inflammatory and immune related signaling pathways, such as TNF signaling pathway, IL-17 signaling pathway, Human cytomegalovirus infection, PPAR signaling pathway and so on. Molecule docking results prompted that GA had fine affinity with IL6 and TNF proteins. Finally, in vivo and in vitro experimental results showed that GA could significantly inhibit LPS-induced CS.

conclusionGA has a potential inhibitory effect on CS, which is worthy of further exploration.

Indexed as

COVID-19 Drug TreatmentDrugs, Chinese HerbalGlycyrrhetinic AcidCytokine Release SyndromeHumansInterleukin-6LipopolysaccharidesMolecular Docking SimulationDrugs, Chinese HerbalGlycyrrhetinic AcidInterleukin-6LipopolysaccharidesCytokine stormExperimental verificationGlycyrrhetinic acidMolecular dockingNetwork pharmacology

Identifiers

PMID35636166
PMCPMC9098921
OpenAlexW4280565342

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.